|Assessment Status||Rapid review complete|
|Indication||For the treatment of moderate-to-severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Upadacitinib may be used as monotherapy or in combination with methotrexate.|
|Rapid review commissioned||21/10/2019|
|Rapid review completed||10/12/2019|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of upadacitinib (Rinvoq®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|
The HSE has approved reimbursement following confidential price negotiations February 2021.